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CHAPTER 1 
INTRODUCTION 
Cerebra-vascular disease, stroke, is a major cause of morbidity 
and death in South Africa. Wyndham (1981), reported that it 
ranked first as a cause of death in the Coloured, second in the 
Asian, third in the White and fourth in the Black population and 
as such is responsible for 10%, 12%, 7% and 8% respectively of all 
deaths in the economically active population of these groups. 
Because the consequences of a cerebra-vascular accident are 
profoundly damaging, any new therapy that may suggest a preventative 
or protective effect, stimulates tremendous interest both in the 
medical profession and amongst the lay public. Many 11 dramatic 11 
and "rational II therapies for cerebral i schaemia such as hypothermia, 
hypocapnia, hypercapnia and hyperbaric oxygen have all been discarded 
as they were regarded as either impractical or because promising 
laboratory results could not be reproduced clinically. 
Following the synthesis of barbituric acid by Von Bayer in 1864, it 
was reported that barbiturates depressed the cerebral metabolic rate 
for 02 (CMR02) and the cerebral bloodflow. There followed other 
reports suggesting a possible protective effect aga inst cerebral 
anoxia and ischaemia in sub-primate experiments. The report by 
Smith et al (1973) initiated an extensive investigation of barbitu-
rate treatment for permanent focal cerebral ischaemia simulating a 
stroke, with other workers investigating global cerebral ischaemia 
to reproduce the event of a cardiac arrest. 
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THE THESIS 
When the research, which forms the basis of this thesis was started 
in 1979, the theoretically attractive situation of transient focal 
cerebral ischaemia simulating a cerebral vessel occlusion followed 
by re-vascularization, had not been specifically investigated with 
barbiturate treatment. 
Cerebral infarction is progressive and evolves over hours, proceeding 
from ischaemia and functional loss to cell death . Sundt et al 
(1969), Crowell et al (1970), Hay~kawa and Waltz (1975). Complete 
recovery is possible if re-vascularization is instituted in time. 
This time interval depends on the regional cerebral bloodflow during 
the period of the vessel occlusion and this bloodflow is provided by 
the collateral circulation. Thus whether infarction results and 
the extent of it, becomes a factor of the period of ischaemia and 
the collateral circulation present. Dujovny et al (1976), 
Morawetz et al (1978), Ojeman et al (1979), Kieck and Crowell (1979), 
Jones et al (1981). This ischaemic period may vary tremendously 
from less than an hour to as much as 5 hours and occlusion times of 
up to an hour can be tolerated without infarction at very low 
regional cerebral bloodflow levels. Morawetz et al (1978), 
Kieck and Crowell (1979), Jones et al (1981) . 
In the clinical situation there wo.uld be an obligatory delay from 
the onset of ischaemia to the institution of barbiturate treatment 
and completion of re-vascularization. Treatment during this period 
would thus be a major contribution if it could afford protection so 
as to allow restitution of cerebral bloodflow before irreversible 
infarction took place. 
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The South African Vervet monkey was chosen for the investigation 
of the effect of barbiturate treatment on transient focal cerebral 
ischaemia in a model simulating the clinical event. In this 
experiment pentobarbital therapy would be delayed for 1 hour to 
provide for the expected delay that would occur from the onset of 
ischaemia to the institution of treatment. Similarly, ischaemia 
was to last 4 hours to allow for a minimum time interval necessary 
to complete the re-vascularization. It was also borne in mind that 
many stroke patients would be older people; the barbiturate dose of 
30mg/kg would be such as to induce prolonged coma but not major 
cardiovascular disturbances with a fall in blood pressure and/or 
cardiac arrest. 
Much of the technique and background knowledge was acquired during 
the year 1977-1978, when I was a microsurgical fellow with 
Drs. R.M. Crowell and R. Ojeman at the Massachusetts General Hospital 
in Boston. 
CHAPTER II 
REVIEW OF THE LITERATURE 
(A) HISTORICAL AND EARLY OBSERVATIONS AND STUDIES 
HISTORICAL 
Barbituric acid was first synthesized from the condensation of 
malonic acid and urea by Adolph van Bayer , working in Ghent in 1864. 
Goodman and Gilman (1970). Barbituric acid is not itself a central 
depressant but the derivatives, the barbiturates, are. The first 
hypnotic barbiturate, diethylbarbituric acid, or barbital, was 
introduced into clinical medicine by Fischer and Von Mering in 1903 
as "Veronal'r and phenobarbital was introduced in 1912 as "Luminal". 
Over the years more than 2500 barbiturates were synthesized and 50 
were marketed for clinical use. Goodman and Gilman (1970). The 
intermediate acting pentobarbital and the ultrashort acting thio-
pental became the most widely investigated barbiturates for the 
treatment of cerebral anoxia and ischaemia. 
METABOLIC AND CEREBRAL BLOODFLOW STUDIES 
In 1932 Quastel and Wheatleyreported that cerebral metabolic studies 
in vitro showed the oxygen consumpti on during gl ucose , lactate and 
pyruvate oxidation could be reversibly reduced f rom 840ul 02 to 
492ul 02 by adding thiopental. 
This was followed by a report by Dameshek et al i n 1934 who, in 
human studies, observed a decrease in the arterio-venous oxygen 
·difference across the brain during anaesthesia wi th sodium amyta l ; 
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this suggested suppression of oxygen utilization. This observation 
was confinned by Schmidt et al in 1945 who showed a definite decrease 
in oxygen consumption in Rhesus monkeys during deep thiopental 
anaesthesia. 
The introduction of the nitrous oxide method for estimating cerebral 
bloodflow (CBF) by Kety and Schmidt in 1945, permitted the more 
accurate calculation of cerebral oxygen consumption under a variety 
of conditions. Using this method, Himwich et al (1947) showed a 
decrease of the cerebral metabolic rate for oxygen (CMR02) of 37% 
in humans during pentobarbital anaesthesia. Wechsler et al (1951) 
also showed the decrease in CMR02 but in addition demonstrated a 
drop in mean arterial blood pressure (MABP) and an increased CBF in 
6 of the 12 patients during thiopental anaesthesia. They postulated 
that some interference with the intracellular mechanism was 
responsible for the decreased CMR02. 
However, in a major study Pierce et al (1962), showed that 
anaesthetic doses of thiopental decreased CMR02 by 52% and CBF by 
48% in man. They argued that this seemed to be secondary to the 
depressive effect of barbiturates on neuronal activity. 
ANOXIA AND BARBITURATES 
During this time, other worke rs invest i gated the effect of various 
anaesthetic agents on experimental anoxia. 
Emerson et al (1942) , reported for the first time on the possible 
protective effect of barbiturates in cerebral anoxia. The study 
was mainly investigating the effect of 10% ethanol on adult mice 
exposed to lethal anoxia in a decompressive chamber, but other 
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animals were also pre-treated with amytal and pentobarbital. 
Whereas ethanol-treated animals showed a significantly improved 
survival, pentobarbital also reduced mortality but to a lesser extent. 
Similarly Snyder (1946), reported prolongation of respiratory effort 
in rabbits who had their tracheas ligated. This was less dramatic 
in the mature animals as compared to the premature new-born. 
Following these pioneering reports of barbiturate action on CBF, 
CMR02 and its possible protective effect, Arnfred and Secher (1962) 
argued that having established that oxygen consumption of cerebral 
cells is reduced by barbiturate, it is natural to assume that 
individuals exposed to a considerable degree of anoxia might be 
protected by this drug and able to resist this insult. They 
presented what was described by them as the first work on the 
protective effect of barbiturates against anoxia and they obviously 
missed or ignored the reports by Emerson et al (1942) and Snyder 
( 1946). 
In a series of reports by Arnfred and Secher (1962), Wilhjelm and 
Arnfred (1965), Wilhjelm (1965) and Secher and Wilhjelm (1968), a 
longer survival time for mice exposed to 2,5% and 5% oxygen and pre-
treated with thiopental to induce quiet sleep, was shown when com-
pared to an untreated awake group. Repeating the study, similar 
results were not only shown for t hiopen tal but also for the anaesthe-
tic agents halothane, cyclopropane , urethane, hydroxydione and 
detrovel. On the addition of CO2, survival times similar to 
thiopental were achieved and when they combined these two agents, 
survival times were prolonged by 300-400%. 
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They speculated that the protective effect was related to the 
sedative and anti-convulsant action of these drugs because control 
animals died agitated and convulsing, suggesting that their increased 
metabolic rate reduced their tolerance to anoxia. They also thought 
that the cerebral vasodilation brought about by adding CO2 with the 
resultant increase in CBF, may have played a role. 
This apparent protective effect lead them to suggest a possible role 
for barbiturates in' clinical practice. In an uncontrolled clinical 
study, using thiopental anaesthesia in caesarian section, they 
concluded that it "did not jeopardize the prognosis of the baby 
although it did make them sleepy. 11 
ANOXIA AND BARBITURATES IN THE NEW-BORN 
The danger of anoxia during delivery and immediately postpartum , 
lead other workers also to investigate a possible protective role for 
barbiturates during this period. 
Snyder (1946), reported prolongation of respiratory effort in 
rabbits following ligation of their tracheas. This was more 
dramatic in the premature new-born rabbit. Campbell et al (1968), 
studied the effect of pre-treatment with pethidine (Meperidine) and 
pentobarbital on the resuscitation of new- born rabbits exposed to 
nitrogen. Whereas both drugs increased the interval to the l ast 
gasp, the barbiturate group had a higher survival rate as wel l. 
Cockburn et al (1969), expanded their experiment to include metaboli c 
and pathological studies. Rhesus featuses, delivered by caesarian 
section had the umbilical cord clamped and their heads covered with 
a bag. The 14 mothers received either local anaesthesia or 
16-43 mg/kg pentobarbital anaesthesia. The pentobarbital reduced 
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the rise of H+ and pC02 during the period of anoxia, in the blood. 
These monkeys only showed brain damage in 3, whereas all 7 control 
monkeys showed extensive damage in the inferior colliculus and brain 
stem, but cortical sparing. 
However, in contrast to Secher and Wilhjelm (1968), who suggested a 
possible role for barbiturates during delivery, they expressed 
doubt whether it could be used as a safe and effective therapeutic 
agent in man. 
ISCHAEMIA AND BARBITURATES 
The earlier work on cerebral anoxia was performed by exposing small 
animals to gas mixtures of no oxygen or low concentrations, or by 
asphyxiating the animal. However, experimental models to produce 
total cerebral ischaemia were being developed and the effect of 
barbiturates tested on them. 
Wright and Ames (1964), described a two-stage procedure in the cat, 
with the carotids temporarily occluded a week after operative 
ligation of all other arteries to the brain. Cats pre-treated with 
12 mg/kg pentobarbital or urea, showed increased survival times when 
compared to controls or ethanol and mannitol treated animals. 
In contrast, Goldstein et al (1966) , reported on a dog model based 
on work by Brockman and Jude (1960), where global ischaemia was 
produced by occluding the ascending aorta and superior and inferior 
venae cavae. Dogs pre-treated with pentobarb ita l needed 13 minutes 
of ischaemia to produce severe neurological damage compared to 8-10 
minutes in morphine anaesthetized dogs. However, when compared to 
a group under ether anaesthesia in Brockman's report, results were 
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very similar. Also the detrimental effect of morphine on cerebral 
ischaemia could have influenced the outcome. Baskin and Hosobuchi 
(1981) and Baskin et al (1982). 
COMBINED ANOXIA AND ISCHAEMIA WITH BARBITURATES 
Whereas the earlier experimental models used either anoxia or ischae-
mia, Yatsu et al (1972), produced both global ischaemia and anoxia in 
a rabbit model by exposing it to 4% oxygen and dropping the blood 
pressure (MABP) to 30 mmHg with trimethapam. A period of 5 minutes 
was timed from the moment an iso-electric electroencephalogram 
(EEG) appeared, at which time the 5 test animals received 5 mg/kg 
of the rapid acting barbiturate, methohexital. 
There was a significant difference in favour of the treated an1mals, 
with all 5 making a full recovery but 3 of the controls dying and 
the other 2 suffering neurological damage. 
The 2 groups were well matched but the authors noted that the time 
to an iso-electric EEG was 2 minutes in the treated group but 4 
minutes in the control group. They expressed concern about this, 
especially when it is stated that ischaemic periods of 3 minutes 
usually lead to full recovery but 5 minutes will result in severe 
neurological damage. The authors speculated on the possible 
protective mechanism but their work offered no explanation for it . 
Thus by 1972 it had been well documentated that barbiturates would 
decrease CBF and CMR02. In addition, an apparent protective effect 
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against global anoxia .and ischaemia was shown i n mice, rabbits and 
dogs. However, protective effects were also shown for other 
anaesthetic agents and many discrepancies were apparent in the various 
experimental models. 
(B) PERMANENT FOCAL ISCHAEMIA 
PERMANENT FOCAL ISCHAEMIA AND BARBITURATES WITH POSITIVE RESULTS 
Following these earlier reports which were directed at the 
investigations of pre-treated sub-primates in global anoxia and 
ischaemia, Smith's report, Smith et al (1973), on the barbiturate 
management in focal cerebral ischaemia, introduced a new dimension 
to this field of study. From then on research during the remainder 
of the decade would be directed at either focal cerebral ischaemia, 
simulating a clinical stroke or globa1 ischaemia to reproduce the 
event of a cardiac arrest. 
Smith, Hoff, Hankinson and co-workers, Smith et al (1973, 1974), 
Smith (1977), Hoff et al (1973, 1975), Hoff and Smith (1977), 
Hoff and Marshall (1979) and Hankinson et al (1974), produced focal 
cerebral ischaemia by clipping the internal carotid and middle 
cerebral arteries in dogs and the middle cerebral artery in ba.boons 
through a small temporal craniectomy using microsurgical techniques. 
Forty-two dogs were divided into groups of 6 each. Four groups 
received halothane anaesthesia as 0,8% ( 11 light 11 ), 1 ,9% ( 11 deep 11 ), 
1,9% p1us hypotension and a group with halothane discontinued prior 
to vessel ligation, 11 awake group 11 • The barbiturate groups received 
pentobarbital 56 mg/kg and th iopental 40 mg/kg prio r t o vessel 
ligation and 40 mg/kg thiopental 15 mi nutes following vessel 
ligation. 
The treated animals fared much better with only 1 dog developing a 
neurological deficit and infarction sizes ranging from 0,1 % to 2,7%. 
In contrast , the halothane animals al l developed neurological defi-
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cits and the infarction sizes ranged from 10% in the "light" group 
to 28% and 34% in the "deep" groups. These results were certainly 
dramatic, especially when compared to the "deep" halothane groups 
and contradicted a protective effect for halothane shown by 
Wilhjelm and Arnfred (1965). 
They speculated on the possible mechanism for this apparent 
protective effect and reviewed the literature on some aspects of 
the 11 steal 11 and inverse "steal" phenomenon, CMR02 and intracranial 
pressure alterations. However, they did not present any data from 
their study to support this. 
These workers repeated the study using baboons. Hoff et al (1975). 
Four groups of animals were either anaesthetized with halothane 
(1,16%) or pre-treated with 60 mg/kg, 90 mg/kg and 120 mg/kg of 
pentobarbital: the neurological and pathological results were not 
dramatically different. One animal of the 4 control animals and 
4 out of 11 of the barbiturate animals died with the infarction 
sizes ranging from 2% to 27% in the control group and 0,5% to 34% 
in the treated groups with an averaged mean of 14,9% and 2,9% . 
respectively. 
However, 2 of the very early deaths in the barbiturate groups 
showed no frank infarction and were regarded as having normal brains . 
This could conceivably have influenced the statistical analyses 
favourably. Even so, they concluded that there was a significantly 
favourable outcome for the high dose barbiturate groups 
(90 and 120 mg/kg) but not for the 60 mg/kg group. They pointed 
out that major cardio-respiratory difficulties were common in the 
high dose group, requiring prolonged ventilation and phenylephrine 
to maintain the blood pressure. 
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Other groups of workers also reported a protective effect for bar-
biturates in primates. Moseley and Molinari and co-workers, 
Moseley et al (1975), Molinari et al (1976, 1977), produced middle 
cerebral artery occlusion in Rhesus monkeys by embolizing them with 
silicone cylinders through the carotid artery. Treated monkeys 
received 4 mg/kg/hr pentobarbital for 12 hours starting within 30 
minutes of the vessel occlusion. Although no significant dif-
ference in mortality and infarction sizes were shown, they concluded 
that their results suggested a better outcome in the treated groups 
because the infarcts were confined to the deep structures and the 
general recovery was better. 
Similarly, Michenfelder and associates, Michenfelder and Milde 
(1975) and Michenfelder et al (1976), having shown some degree of 
protection in squirrel monkeys but not in cats or dogs, reported on 
an experiment using Java monkeys with middle cerebral artery 
occlusion. Treated monkeys received 14 mg/kg pentobarbital, 
delayed for 30 minutes followed by 7 mg/kg every 2 hours for 48 
hours. Although all parameters monitored were similar in the 2 
groups, the individual monkey weight is not given but only the range 
as 0,8 to 1,9 Kg, which is important because lighter and younger 
monkeys may tolerate ischaemia better . . 
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The 9 barbiturate monkeys fared much better, all an i mals surviving , 
with 4 showing neurological deficits and infarction in contrast to 3 
of the control animals that died with 8 showing neurological deficits 
and i.nfarction. Even so, they cautioned against a hasty clinical 
application and pointed out that many promising laboratory regimes, 
including hypercapnia, hypocapnia, Dextran 40, steroids, glycerol 
"c. ~ and serum albumin, have all fallen by the wayside. 
PERMANENT FOCAL ISCHAEMIA WITH EQUIVOCAL OR NEGATIVE RESULTS 
In contrast to the apparent protective effect shown by the previously 
reviewed work, a number of reports appeared showing equivocal or 
negative results. 
Michenfelder and Milde (1975), reported on a series of multiple 
experiments involving gerbils, cats, dogs and squirrel monkeys. 
They showed no protection in the gerbils, cats or dogs treated with 
pentobarbital and concluded that it does provide a degree of 
protection but it is only consistently demonstrated in the primates. 
Lightfoote et al (t977), reported a lower yield of infarcted hemi-
spheres in pentobarbital treated gerbils but this incidence of 37% 
was the same as that reported by Berry et al (1975) with the use of 
Ketamine. Unusual was the report by Black et al (1978), where 7 of 
10 cats pre-treated with 50 m~kg pentobarbital, died within 50 hours 
of ischaemia, although the infarction size was only 1,49% compared to 
the control group with 17,2% infarction and only 1 death. 
On the other hand, Dujovny et al (1976) and Yonas et al (1980a), 
showed no protection in dogs with middle cerebral artery ischaemia 
and pre-treated with 25 mg/kg pentobarbital. Similarly, Selman 
and Spetzler (1980) and Selman et al (1981b), showed no protection 
in baboons with pentobarbital therapy delayed for 30 minutes and 
maintained for 96 hours. In fact, 4 of the 5 animals died with 
massive infarction and oedema; in contrast, all 5 controls survived. 
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PERMANENT ISCHAEMIA AND DELAYED BARBITURATE TREATMENT 
Whereas in most of the earlier work animals were pre-treated with 
barbiturates, other workers did delay the treatment for a short 
period of up to half an hour. Smith et al (1973), Moseley et al 
(1975), Michenfelder et al (1976). Although these experimenters 
tri ed to simulate the clinical event of a stroke, they agreed that 
it was un l ikely that a physician would be able to institute therapy 
within this time interval. A number of workers specifically 
investigated the interval that therapy could be delayed for and 
still provide protection against ischaemia. 
McGraw (1977) and Levy and Brierley (1979), presented work on 
gerbils made ischaemic by carotid artery ligation. McGraw delayed 
treatment for 1 hour but these animals did not show any protection 
when compared to animals anaesthetized with ether and treated with 
saline. In contrast, Levy and Brierley delayed therapy for 2 hours 
and concluded that the treated animals showed less shift of the 
brain and ischaemic neuronal changes and that delayed treatment 
does protect against ischaemia. However, a major criticism of 
their work is that the untreated animals showed significantly more 
motor activity and seizures with a resultant increased metabolic 
state. Disburbing also is the work by Black et al (1978), where all 
10 cats treated with 50 mg/kg pentobarbi ta l afte r a delay of 2 hours 
died, compared to only 1 in the control group . 
Whereas the results in these smaller animals yielded rather 
unconvincing evidence, Corkill et al (1976) and Yonas et al (1980a), 
expanded the experiment in dogs and investigated various intervals 
of delayed therapy. Corkill et al concl uded t hat a 1 hour del ay 
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could still provide protection but not if therapy was given at 
3 or 6 hours following the onset of ischaemia. Similarly, 
Yonas et al investigated pre-treatment with pentobarbital and 
15 minutes, 2 hours and 4 hours of delayed treatment with thiopental. 
Although no untreated controls were investigated, they showed, 
rather surprisingly, an apparent protective effect in the delayed 
thiopental groups compared to the pre-treated pentobarbital group~ 
These authors having shown an apparent protective effect for treat-
ment delayed as long as 4 hours, speculated on why this should pro-
vide some protection. Levy and Brierley admitted that the 
sedative and anti-convulsant action might have played a role but 
suggested that suppression of the hypermetabolic state at 3-4 hours 
post ischaemia, would allow limited energy stores to be available 
for maintaining cell integrity. Both Corkill et al (1976) and 
Yonas et al (1980a), suggested that the micro-collateral circula-
tion was protected. It was shown to begin to fall at 3 hours post 
ischaemia with peri-vascular oedema or intravascular thrombogeneses 
amongst the possible responsible factors. 
BARBITURATE DOSAGE STUDIES 
In the earlier reported work, a variety of dosage regimes were used. 
Arnfred and Secher (1962), endeavoured to induce quiet sleep 
whereas Smith et al (1973) and Hoff et al (1975), used a wide range 
of dosages without stating the reason for this. Michenfelder 
et al (1976), stated that their dosage regime was an empiric one to 
obtain moderate anaesthesia compatible with adequate haemodynamics. 
They pointed out, however, that a more rational approach would have 
been an EEG burst suppression end- po int , indicating a relatively 
15 
deep anaesthesia and adequate haemodynamics. Several investigators 
directed themselves to this problem experimentally. 
Hankinson et al (1974) and Steen and Michenfelder (1979), showed in 
dogs and mice respectively that optimum barbiturate effect was 
related to a dose of 60 mg/kg. Whereas Hankinson demonstrated 
considerable variability with lower dosage regimes, Steen showed a 
linear relationship up to the optimum dose of 60 mg/kg after which 
further increases lead to a decline in survival time. 
In contrast, Corkill et al (1978), investigating doses of 10, 15; 20, 
40, 50 and 80 mg/kg pentobarbital, demonstrated significant 
reduction of infarct sizes in dogs receiving 15-20 mg/kg. 
Increased doses did not alter the outcome and in fact, 2 animals in 
the 50-80 mg/kg group died. On the other hand, Yonas et al (1979), 
found that 40 mg/kg as well as 80 mg/kg thiopental protected in dogs 
compared to the animals that received 25 mg/kg pentobarqital. Thus 
it was shown that not only would a considerable variation of dosage 
regimes seem to afford protection against ischaemia, but also dif-
ferences between thiopental and pentobarbital became apparent. 
BARBITURATE PLASMA LEVELS 
Miller (1979) and Bruce et al (1978), questioned the usefulness of 
barbiturate plasma levels as an index of therapeutic efficacy. A 
number of the other workers though, thought that it may be useful 
to determine dosage regimes. Whereas Yonas et al (1979) showed 
that plasma levels of 0,93 to 1,65 as well as levels of 1 ,95 to 
4,97 ug/ml afforded protection in 2 groups of dogs, Weidler et al 
(1979), reported different results. In cats with middle cerebral 
artery ischaemia, blood levels of more than 30 ug/ml were 
16 
associated with death while the survivors had levels less than 
30 ug/ml. They speculated that the combined effect of cerebral 
ischaemia and barbiturates may be detrimental to the heart, accoun-
ting for some of the delayed deaths. 
In an attempt to overcome the major cardio-vascular problems 
associated with high dose barbiturates, Selman et al (1981a), 
titrated the administration to the EEG and blood pressure response. 
A ·1oading dose of 30 mg/kg, followed by a continuous infusion of 
0,75-12,5 mg hourly, resulted in a consistent iso-electric EEG with 
few adverse cardio-vascular problems and an average barbiturate 
plasma level of 27,3 ug/ml. Using this dosage regime, they showed 
an apparent protective effect in baboons with transient middle 
cerebral artery ischaemia but not with permanent occlusion of this 
vessel. 
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(C) GLOBAL ISCHAEMIA AND ANOXIA 
The earlier experimental workers on global anoxia and ischaemia, 
Emerson et al (1942), Snyder (1946), Arnfred and Secher (1962), 
Wilhjelm and Arnfred (1965), Wright and Ames (1964) and 
Goldstein et al (1966), used mice and dogs to study the effect of 
pre-treatment with barbiturates on the survival times of these 
an imals. Following this, Bleyaert et al (1977, 1978), developed 
a monkey model and initiated a series of investigations to study 
the effect of high dose barbiturate treatment for global ischaemia 
simulating the clinical event of a cardiac arrest. 
Global ischaemia was produced for 16 minutes in Rhesus monkeys by 
applying a high pressure neck tourniquet with simultaneous 
trimethaphan induced hypotension. Animals treated with 90 mg/kg 
thiopental at 5 and 15 minutes and 120 mg/kg at 60 minutes, showed 
a significantly improved outcome compared to untreated animals and 
those with treatment delayed for 30 minutes in the 120 mg/kg group, 
all of which showed no protection. These results, they thought, 
suggested that treatment should be instituted early, although they 
could not explain the paradoxical outcome of treatment at 30 and 
60 minutes in those who received 120 mg/kg barbiturate. 
However, a number of unresolved questions and discrepancies were 
present in their work. Although the 5-minute treated group is given 
a zero (no deficit) neurological score, they stated that some of the 
animals were ataxic, a sign that merits a score according to their 
model. It is also strange that 120 mg/kg at 60 mi nutes should 
afford protection but not at 30 minutes. They also referred to 
unpublished data where controlled ventilation in monkeys paralysed 
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with pancuronium reduced neurological damage significantly • . 
This raised the question of how much the barbiturate effect was due 
to sedation and immobilization. 
In contrast to the above study, Steen et al (1979) and Jackson 
et al (1979), could not show any protective effect in dogs with 
8-12 minutes of global ischaemia produced by ligating the ascending 
aorta and both venae cavae. Dogs were treated either prior to 
ischaemia or at 10-12 minutes post ischaemia. Major cardiovascular 
and respiratory difficulties were encountered necessitating 
dopamine infusion in the Jackson study. Steen et al (1979), stated 
that this supported their contention that the most likely mechanism 
of barbiturate protection in focal ischaemia is related to the 
reduction of the cerebral metabolic rate and such a reduction would 
not be expected in total global ischaemia. Similarly, Snyder 
et al (1979), in a different dog model, where global anoxia was 
produced by plugging the endo-tracheal tube, showed no benefit 
with barbiturate treatment. 
Even so, Breivik et al (1978), as a direct result of their Rhesus 
monkey studies, devised a protocol for an uncontrolled feasibility 
trial of barbiturate therapy during cardiac resuscitation follow-
ing an arrest in humans. This was issued to 20 centres around 
the world and Safar et al (1979) and Safar (1980), reported that 
the proportion of severely damaged patients was no higher compared 
to the standard method of resuscitation. This was followed by 
the introduction of an international pilot study and Detre et al 
(1981), reported that the attempt proved feasible and that a 
prospective randomized clinical trial was to be undertaken. 
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(D) TRANSIENT FOCAL ISCHAEMIA 
Whereas global anoxia and ischaemia and permanent focal ischaemia 
became quite extensively investigated, the theoretically 
attractive situation of transient focal ischaemia with -barbiturates 
was not. At the time I started my research in 1979, there was no 
reported work which specifically investigated this event. However, 
two reports were published in 1981, where this was specifically 
investigated in dogs and baboons. 
Yonas et al (1981), investigated the 11 grace 11 period in transiently 
focal ischaemic dogs after which revascularization will result in 
improved neurological outcome. Treated animals that received 
20 mg/kg thiopental followed by 10 or 20 mg/kg for 2 to 3 hours, 
commencing 15 minutes after middle cerebral artery embolisation, 
were compared to dogs pre-treated with 25 mg/kg pentobarbital and 
to a group of dogs reported on previously by _them. Dujovny et al 
(1976). A middle cerebral artery embolectomy was performed after 
6 hours and the outcome in the thiopental group was significantly 
better compared to the pentobarbital group. This group, in fact, 
did very poorly with all animals showing neurological deficit and 
infarction. They then concluded that the 11 grace 11 period had been 
extended from5 to 6 hours by thiopental, based on their previous 
work, Dujovny et al (1976), wh ich showed that an embolectomy done 
after 5 hours would result in haemorrhagic infarction. 
However, these results and conclusion do raise a number of questions. 
Although the pentobarbital dose was less than the thiopental regime, 
it did not provide protection. They claimed that the 11 grace 11 
period had been extended from 5 to 6 hours but in their previous 
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report, Dujovny et al (1976), only embolectomies at 3, 4, 5 and 
7 hours are mentioned and discussed in the text, though a 6 hour 
period did appear in one of the tables, showing infarction. 
Also, no group of dogs without any barbiturate anaesthesia was 
available to serve as controls. Lastly, similar extensions of 
the 11 grace 11 peri.od for dimethyl sulfoxide (DMSO) and methyl-
predniso1one were shown by them. Dujovny et al (1979). 
Similarly, Selman et al (1981b), reported apparent protection in a 
baboon model with 6 hours of middle cerebral artery occlusion . 
However, whereas the treated group was in barbiturate coma for 
96 hours and ventilated, the control animals were awake and 
breathing spontaneously. The control animals developed severely 
raised intracranial pressures and infarcts compared to normal 
pressure and minor pathological changes in the treated group . 
However, the ventilated animals showed much better oxygenation, 
with the arterial p02 being 115-160 mmHg, compared to 70-110 mmHg 
in the control animals. One can thus only speculate as to how much 
the mechanical ventilation played a role in the better outcome of 
the treated ani.mals. 
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(E) BARBITURATES COMPARED TO OTHER DRUGS 
In the earlier work, protective effects were shown for other drugs 
during cerebral anoxia and ischaemia. Emerson et al (1942), 
investigated 10% ethanol as the major agent and to a lesser degree, 
barbiturates. Similarly, Wilhjelm and Arnfred (t965), showed 
inc reased survival times for anoxic mice treated with halothane, 
· cyclopropane, urethane, hydroxydione, detrovel and also for CO2. 
Whn e Wright and Ames (1964), showed some benefit with urea 
treatment in global ischaemi a . 
Recently, a number of agents were investigated in conjunction with 
barbiturates. Whereas Steen et al (1978), found that diazepam 
(7,5 mg/kg) did increase survival times in hypoxic mice, it was not 
as good as mephobarbital. In contrast, Siemkowicz (1980), showed 
as good an outcome for diazepam compared to -pentobarbital in hyper-
glycaemic ischaemic rats. In contrast to Steen et al (1978), who 
suggested that the effect is related to the anaesthetic action, 
Siemkowicz maintained that the anti-convulsant action which thus 
prevents a hypermetabolic state, plays a role. On the other hand, 
Aldrete et al (1979), showed that phenytoin treated ischaemic 
rabbits had an improved outcome compared to a placebo and thiopental 
treated group, but thought that thi s anti-convu·lsant acted by 
reducing CBF, CMR02 and preven ted K+ l eakage from the cell . 
Tamura et al (1979), also compared pentobarbital t o a new imidazole 
derivative and as good an outcome with the imidaz.ole agent and much 




(F) MODE OF ACTION OF BARBITURATES 
The apparent protective effect of barbiturates had many workers 
investigating the possible mechanism for this. Following the 
original observation and studies on cerebral metabolic rate and 
cerebral bloodflow by Quastel and Wheatley (1932), Kety and 
Schmidt (1945), Himwich et al (1947) and Pierce et al (1962), 
numerous other reports attempted to explain this action. 
ANAESTHETIC EFFECT 
Steen and Michenfelder (1978, 1979), concluded after showing a 
protective effect for only the anaesthetically active isomer and 
racemic form of mephobarbital, that the effect was related to the 
anaesthetic action of barbiturates and not to the anti-convulsant 
action. However, Siemcowicz (1980), showed a significant protective 
effect for diazepam and thought it was related to the anti-convulsant 
properties. In contrast, Aldrete et al (1979), thought that the 
anti-convulsant drug, phenytoin, protected by decreasing CBF, 
cerebral metabolic rate and K+ leakage from the cell. 
METABOLIC STUDIES 
Following cerebral anoxia or ischaemia, the energy stores of ATP 
and phosphocreatine become rapidly depleted with accumulation of 
lactic acid and a fall in pH. 
The earlier work by Quastel and Wheatley (1932), Pierce et al (1962) 
and others, showed that barbiturates decrease CMROz significantly. 
In a series of experiments by Gatfield et al (1966), Michenfelder 
and Theye (1970, 1973), Michenfelder (1974), Michenfelder and Milde 
(1975, 1977), Sundt et al (1979), Nilsson and Siesjo (1975) and 
Kofke et al (1979), it was further shown that this metabolic 
depression was dos~ dependent and occurred only until the EEG 
became isoelectric. Also the rate of ATP and phosphocreatine 
depletion and lactate accumulation,was clearly lower in barbitu-
rate treated animals. It was also shown that there was no 
alteration in the cerebral metabolic pathways or of the intra-
cellular redox state, with the brain concentrations of ATP, 
lactate, pyruvate and phosphocreatine unchanged but with an increase 
in glucose. Thus it was speculated that barbiturates cause 
neuronal depression and thus reduced metabolic activity and energy 
requirements, rather than altering metabolic pathways, to make the 
brain more tolerant to anoxia and ischaemia. 
In contrast, Nilsson (1971) and Nordstrom et al (1977), showed that 
barbiturates did not affect ATP depletion, lactate accumulation, 
CMR02 or CBF during anoxia or ischaemia. Similarly, Nemoto and 
Frinak (1979), found no improvement in the brain oxygenation and pH 
in ischaemic rats. Nordstrom concluded that the protective effect 
does not seem to be a consequence of reduced energy requirement. 
Whereas Michenfelder and associates and Gatfield et al (1966), 
showed that the metabolic depression is related to the anaesthetic 
dose with no change in the metabolic pathways, Crane et al (1978) 
and Hakim and Moss (1976), reported different results. Crane 
showed that a major decrease in the CMR for glucose occurred with 
only 10-20% of the usual anaesthetic dose and argued that small sub-
anaesthetic doses should theoretically also be protective. Hakim 
found 25% increase in the pentose phosphate pathway induced by 
barbiturates at the expense of the Krebs-cycle and suggested that 
this alteration may be a protective measure facilitated by barbitu-
rates. 
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MEMBRANE AND CELLULAR STABILIZATION 
It has been speculated further that barbiturates protect by 
stabilizing membranes and thus prevent the secondary events that 
may follow on cellular failure and the release of substrates. 
Whereas Nemoto et al (1977), showed that barbiturates reduced the 
cyclic AMP (adenosine monophosphate), Akiguchi et al (1980), 
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reported that the dopamine and nor-epinephrine depletion of the 
cerebral vessel during ischaemia was reduced. These authors sug-
gested that prevention of a cyclic AMP-catecholamine induced change 
will be beneficial during ischaemia. Similarly, Astrup et al (1977), 
showed that the K+, Na+, ca++ and Mg++ loss from the cells were 
reduced or prevented by barbiturates during ischaemia and suggested 
that this maintains the cellular metabolic machine. 
In contrast, Wade and Sorenson (1978), reported a marked increase in 
the CSF K+ during ischaemia which was not influenced by barbiturates. 
They concluded that the barbiturate action was different to that of 
hypothermia, which will delay this K+ rise. 
FREE RADICAL SCAVENGING 
The reduction of the cerebral metabolic rate could not explain the 
apparent protective effect of barbiturates in transient total 
global ischaemia. Demopoulos et al (1977a, 1977b) and Flamm et al 
(1977, 1979), advanced a hypothesis that barbiturate protection may 
be linked to the ability to scavenge or neutralize free radicals. 
These substances which are molecules with an unpaired electron in an 
outer orbit and present in a high energy state, can cause the 
alteration and fragmentation of the molecular membrane. This is 
reflected in the alterations of components such as cholesterol and 
free fatty acids (FFA) with consumption of the normally occurring 
anti-oxidant, ascorbic acid. 
Demopoulos (1977a, 1977b), Flamm (1977, 1979), Majewska et al (1978) 
and Yoshida et al (1980), showed that methohexital and pentobarbital 
reduced and controlled these free radical reactions and improved the 
anti-oxidant ability of the brain. 
However, Smith et al (1980) and Nemoto et al (1981), reported no 
inhibition of these free radical reactions with phenobarbital and 
pentobarbital but some with thiopental and methohexital. However, 
whereas Smith et al (1980), concluded that barbiturate protection 
is unrelated to free radical scavenging, Nemoto et al (1981), 
thought differently. They stated that in terms of the major FFA, 
pentobarbital did show a significant reduction in the release of 
arachidonic acid and postulated a protective effect which is 
exhibited by this action. 
OEDEMA FORMATION AND INTRACRANIAL PRESSURE 
Earlier observation by Horsley (1937) and Shapiro et al (1973), 
indicated that barbiturate anaesthesia will reduce intracranial 
pressure in humans. Smith et al (1973) and Corkill et al (1976), 
suggested that barbiturates prevented peri-vascular oedema and 
elevation of intracranial pressure following cerebral ischaemia as 
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a possible mechanism to explain their reported barbiturate protection. 
Smith and Marque (1976), Simeone et al (1979) and Lawner et al (1979), 
investigated the effect of barbiturates. Experimentally produced 
cerebral oedema was significantly reduced by barbiturates and 
Innovar when compared to control or hypothermic animals. 
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On the other hand, Harbaugh et al (1979), showed a prompt decrease 
in intracranial pressure associated with a simultaneous drop in 
arterial blood pressure but found no alteration in the water and 
Na+ content of the oedema fluid. 
In contrast, Selman et al (1980), found that barbiturate treated 
baboons with permanent occlusion of the middle cerebral artery, 
developed marked elevation of intracranial pressure. Thus a wide 
variation had been reported on the effect of barbiturates on 
cerebral oedema and intracranial pressure. 
Whereas Smith and Marque (1976), concluded that the protective effect 
of barbiturates is related to reducing the peri-vascular oedema, 
Harbaugh et al (1979), thought the action was more related to 
decreasing cerebral blood volume and brain capillary pressure. 
HYPOTHERMIA 
Since barbiturates interferi with temperature control regulation, a 
degree of accidental hypothermia may have contributed to the 
beneficial effect. Hypothermia as such, has been widely investi-
gated as a protective adjunct for cerebral ischaemia with contra-
dictory experimental and clinical results. Pontius et al (1954), 
McMurrey et al (1956), Rosomoff (1959) and McDowal1 (1971). 
Lafferty et al (1978) and Nordstrom and Rehncrona (1978), reported 
synergistic effects for combined hypothermia and barbiturates, 
achieving CMR02 depression at 30°C that usually occurs at 22°C . 
However, Hagerdal et al (1978), failed to show this synergism. 
Whereas Hagerdal showed better results with hypothermia compared to 
barbiturates, Steen and Michenfelder (1979), reported similar 
survival times for 29°C and barbiturates in hypoxic mice. 
CEREBRAL BLOOOFLOW ANO THE 11 STEAL 11 PHENOMENA 
Lassen (1959) and Lassen and Palvalgyi (1968), showed that bloodflow 
may be diverted from the maximally vasodilated ischaemic areas by 
vasodilation in the non-ischaemic brain regions, the "steal" 
phenomenon. The converse may also happen and flow may be increased 
by vasoconstriction in the non-ischaemic regions, the 11 inverse-
steal II phenomenon. Barbiturates were thought to be cerebral vaso-
constrictors, Pierce et al (1962) and Marsh et al (1977), and as 
such would increase bloodflow in the ischaemic area through the 
11 inverse-steal 11 mechanism. 
Hanson et al (1975), found no evidence of an ''inverse-steal" effect 
for barbiturate. In contrast, Branston et al (1979), reported that 
in ischaemic regions which s~owed an iso-electric EEG and CBF below 
20cc/l00gm/minute, methohexital increased CBF. This did not occur 
if the CBF was more than 25cc/\00gm/minute and the EEG showed elec-
trical activity. They concluded that this was due to an 11 inverse-
steal11 phenomenon. 
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HoHever, Marin et al (1981), found pentobarbita l to inhibit spontaneous 
mechanical activity and tone in the isolated human artery in vitro. 
The relaxation was dose dependent and linked to ca++. They concluded 
that these observations disagree with the hypothesis that barbitu-
rates directly constrict cerebral arteries although they agreed it 
may constrict the arterioles. 
(G) CLINICAL APPLICATION 
The apparent protective effect of barbiturates on hypoxic mice, 
Arnfred and Secher (1962), lead these workers, Secher and Wilhjelm 
(1968), to suggest a possible role for it in clinical practice. 
They concluded from an uncontrolled study, where mothers were 
induced with thiopental anaesthesia for caesarian section, that 
this 11 did not jeopardize the prognosis 11 of the baby. Similarly, 
Smith et al (1974), stated that they believed barbiturates deserved 
a clinical trial as an anaesthetic or anaesthetic supplement. 
Others, Cockburn et al (1969) and Michenfelder et al (1976), 
cautioned against the premature use and Smith (1977), pointed out 
that even though it seemed 11 rational" to use it, there was no 
clinical data to support this. 
However, Breivik et al (1978) and Safar (1980), developed a protocol 
for a feasibility trial of barbiturate therapy in resuscitation 
following cardiac arrest. This was followed with the introduction 
of a 3 year (1979-1982) international multicentre, randomized 
clinical study. Detre et al (1981), reported on the preliminary 
analysis of the first 85 cases and concluded that the attempt at 
a prospective randomized clinical study, was feasible. 
On the other hand, no controlled prospective trial for barbiturate 
use in focal cerebral ischaemia or raised intracranial pressure in 
clinical practice had been introduced. A number of case reports 
and uncontrolled patient series had appeared in the literature with 
Geevarghese et al (1977), Hoff et al (1977), Lawner and Simeone 
(1979), Woodhurst et al (1980), Bennet (1980), Kassel et al (1980), 
Belopavlovic and Buchtal (1980b) and Rose et al (1981), reporting 
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on the use in cerebral ischaemia, while Marshall et al (1978, 1979), 
used barbiturate coma in raised intracranial pressure following 
· trauma or during metabolic coma (Reye's syndrome). · 
. 30 
It was shown that humans could tolerate high dose barbiturate therapy 
although Belopavlovic and Buchtal (1980b), had to use dopamine to 
mai ntain the blood pressure in one of their patients. Yonas et al 
(198Gb), introduced a regime of a series of decreasing doses of 
thiopental after the CVP and/or wedge pressure was elevated to 
achieve a rapid high barbiturate blood level without causing cardio-
vascular and respiratory depression. Stanski et al (1980), further 
showed that the pharmacokinetics of barbiturates altered during high 
dose treatment. The barbiturate elimination changes from the first 
order or linear to non-linear with an apparent increase in the half-
life. 
However, Kassel et al (1980), reported on 12 patients with subarach-
noid haemorrhage and spasm treated with barbiturate coma with 11 
deaths. They concluded that although these discouraging results 
were most probably a reflection of the patient's condition, 
barbiturate therapy should be limited to patients with life 
threatening conditions until such time that further evidence of its 
usefulness becomes manifest. 
CHAPTER III 
MATERIALS AND METHODS 
(A) ANIMALS 
Thirty South African Vervet monkeys of both sexes, weighing on the 
average 5,8 kg, were used. The animals were obtained from the 
Cape Provincial Animal Centre, Delft, at Kuilsriver where they had 
been quarantined and acclimatized. The week prior to the experi-
ment, they were transferred to the University of Cape Town Animal 
House which is a fully equipped facility attended by trained 
technical staff. Monkeys were alternately assigned to either the 
Barbiturate or Control group. 
(B) ANAESTHESIA 
The animals were starved overnight and after induction of anaesthe-
sia with 7 mg/kg of Ketalar intramuscularly at 7.30 a.m., they were 
taken to the Jan S. Marais Surgical Laboratory. The monkeys were 
intubated with the appropriate size endotracheal tube and mechani-
cally ventilated with a 40% 02 and 60% N20 mixture. Anaesthesia 
was maintained by adding 0,5% to 1% Halothane intermittently so as 
to have the monkey as close to being awake as possible and thus 
minimize the drug effect on the experiment. It was not necessary 
to paralyse the monkeys as they tolerated the ventilation easily 
which was set at a rate of between 14 and 16 breaths per minute 
and adjusted if necessary. 
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(C) SURGERY/MONITORING 
This was performed under normal sterile surgical technique. The 
left upper thigh was shaved and prepared with Betadine. The 
femoral artery and vein were exposed below the inguinal ligament 
and medium size catheters introduced with permanent ligation of the 
vessels. The arterial line was connected to a pressure transducer 
fo r conti nuous blood pressure monitoring. The venous line was used 
for intravenous fluid and drug administration. Ringers Lactate was 
given at a rate of 30% blood volume during the first hour and 10% 
per hour for the rest of the experiment. Ampicillin 250 mg was 
given at this time. The first blood gas analysis was also done at 
this stage and the necessary respiratory adjustments made. Further 
blood gas determinations were made at 1 to 2 hourly intervals or 
more often when indicated. Continuous rectal temperatures were 
measured and intermittent warming with a heating fan applied to keep 
the temperature at 37°C. 
The monkey was then placed in an Animal Stereotaxic frame so as to 
have the right orbit accessible. This area was shaved, prepared 
and draped with sterile surgical drapes . The operating microscope 
was then introduced for a transorbital microsurgical exposure of 
the anterior circle of Willis as first suggested by Sundt. 
01 Brien and Waltz (1973) (Fig. I, II and III). The skin was 
incised along the supra-orbital ridge f rom the lateral to the medial 
ca nthus, using a bipolar diathermy to control bleeding. The peri-
osteum was stripped down , staying outside the periorbita in an 
attempt to keep this intact and to prevent the bulging orbital fat 
from making surgery unnecessarily difficult. 
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FigWte. I: 
F igWte. II : 
01tbila.l a11.e.a .6ha.ve.d 601t in.Wion. a.long .6up1ta.-
01tbila.l mall.gin. 
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The pupil was then incised horizontally with a number 11 surgical 
blade to remove the aqueous humor and vitreous body. Dissection 
was now carried to the posterior aspect of the orbit by retracting 
the empty eye downwards, coagulating and cutting bridging orbital 
arteries and veins. The optic nerve, now exposed at the apex and 
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the cone of orbital muscles, was coagulated with the bipolar diathermy 
and cut, taking great care in the vicinity of the ophthalmic artery, 
as bleeding at this stage would be difficult to control. 
The eyeball, then freed at the apex, was removed in order to leave 
an empty orbit, with the eyelids intact: further soft tissue dis-
section was carried out at the apex to expose the optic strut and 
optic canal. Using the dental drill, a 5-7 mm hole was drilled at 
the apex, taking the optic strut, lateral half of the optic canal 
and a small area of adjacent sphenoid wing. Great care was taken 
not to transgress the dura and cause subarachnoid haemorrhage or 
vascular trauma to the underlying carotid artery and its branches. 
Haemorrhage from bone was controlled with bone wax. 
The dura mater and arachnoid was carefully opened and refl~cted, 
exposing the frontal and temporal lobes, the internal carotid artery, 
the bifurcation with the perforators, the anterior cerebral artery 
curving medially across the optic nerve and the middle cerebral 
artery running laterally, in the shallow Sylvian fissure. Care 
was taken not to cause any haemorrhage at this stage. (Fig. IV) 
. 35 
FigWte. III: 
F igu1te. IV: 
View tYlll.ough miCJLo-0cope.: 
1. Inte.Jtna.l cMo:ud 
aAJ:. e.Jtlj 
2. Antvuo1t ce.1te.b1ta.l 
aAJ:.eJtlj 
3. Middle. ce.1te.b1ta.l 
MJ:.e.Jttj 
4. Optic neJtve. 
5. P e.Jt 6 o Jta..ting aM.e.Jttj 
A Lewis aneurysm clip was then applied to the proximal middle 
cerebral artery just beyond the bifurcation and proximal to the 
small perforators coming off it. The orbit was then filled with 
saline warmed to body temperature and covered with a surgical swab. 
(0) BARBITURATE DOSAGE/BLOOD LEVEL 
The barbiturate group received a total dosage of 30 mg/kg of 
pentobarbital (May Baker) intravenously after 1 hour of middle 
cerebral artery occlusion. The timing was to simulate the expected 
delay in the clinical situation of a patient who had suffered a 
stroke. Half the dose of pentobarbital, 15 mg/kg, was given as 
quickly as possible, being guided by the blood pressure, so as not 
to let it drop below a mean of 60 mm of mercury, an arbitrary level 
at the lower limits of autoregulation. This usually took about 5 
minutes. The remainder was then given slowly over the next 20 to 
25 minutes, again guided by the blood pressure. 
Thus the total dosage was given over 30 minutes. One should note 
that in the clinical situation one would be dealing with older 
patients who have a low tolerance to high dose barbiturates and a 
precipitous drop in blood pressure could aggravate the stroke or 
induce cardiac collapse . 
Blood levels of pentobarbital were determined at various stages by 
Dr. Dave Morrel of the Department of Anaesthesia, using the gas 
liquid chromatography method: blood was taken half an hour after 
the full dose was given and again at the time of de-occlusion of 
the middle cerebral artery. 
ml. (Ug/ml) 
Levels were expressed in mic~ograms/ 
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(E) DE-OCCLUSION 
After 4 hours the Lewis clip was removed. The patency of the 
artery was tested with an intravenous injection of 1 cc Methylene 
Blue. Patency was confirmed through the operating microscope by 
rapid filling in the antegrade direction and not early retrograde 
filling, with a pale segment distal to the site of clip application. 
The orbital defect was covered with gelfoam and the orbit filled 
with Methyl-Methacrylate injected as a liquid with a 20 cc syringe. 
The skin incision along the supraorbital margin and the palpebral 
fissure were sutured with 3/0 silk. The arterial and venous lines 
were removed, the vessels ligated and the skin sutured with 3/0 
silk. All wounds were sprayed with a surgical plastic spray. 
Animals were allowed to wake up and once breathing adequately, they 
were extubated and returned to their cages. Usually this was 
between 3-6 p.m., the animals having been in the surgical laboratory 
for 7 to 10 hours. 
(F) NEUROLOGICAL EVALUATION 
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At this stage a careful neurological evaluation was usually not 
possible. The control group monkeys were still drowsy, whilst the 
barbiturate group monkeys were in a deep coma. Thus a careful 
neurological assessment was performed early the next morning and 
daily in the survivors till sacrificed. The following was noted: 
level of consciousness, presence of a hemianopia to food presentation 
or threat, abnormal leg posture, power assessment testing the 
animal's ability to grip objects or to support his weight and the 
direction of circling. Using these criteria, a simple practical 
scale was used so that animals could be neurologically graded with 
confidence as follows: 
GRADE I: 
GRADE II: 
No abnormality detected: 
Normal 
Minimal abnormality i.e. hemianopia, 
abnormal posture or grip, circling 
to one side: 
Minor stroke 
GRADE III: Significant weakness, but some 
movement: 
Moderate stroke 
GRADE IV: Hemiplegic, no movement, drowsy: 
Maj or stroke 
GRADE V: Death: 
Death 
(G) PATHOLOGICAL EVALUATION 
Those monkeys that died overnight or during the subsequent days, 
had their brains perfused in situ with buffered formalin and then 
removed to be immersed in buffered formalin for another 6 weeks. 
The surviving monkeys were sacrificed at 2 weeks to allow infarcts 
to mature and thus become well demarcated and readily detectable. 
Monkeys were anaesthetized with 100 mg of Ketalar intramuscularly 
and brains perfused in situ with buffered formalin and then 
immersed for 6 weeks after removal. 
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The brains were cut, processed and stained with H +Eby 
Mr. Casiano Gouveia of the Department of Pathology and 
Mrs. Heather Mcleod of the Department of Surgery. · The neuro-
pathologica l assessment was done by Dr. Richard Hewlett of the 
Department of Neuropathology, Tygerberg Hospital, with the author 
in attendance but not knowing the experimental history of a 
particular brain examined. 
Brains were cut coronally, the first anteriorly through the optic 
chiasm and then rostrally and caudally in 4 mm sli ces. The slices 
were examined for infarct size, location, presence of haemorrhage, 
microscopic evidence of neuronal death and acute ischaemic changes. 
Again a simple practical scale was used to grade the pathological 
findings as follows: 
GRADE I: No changes: Normal 
GRADE II: Microscopic evidence only, 
ischaemic infarction: Microscopic 
GRADE I II: Macroscopic infa rction: Macroscopic 
<1 cm in diameter <1 cm 
GRADE IV: Macroscopic infarction: Macroscopic 
>1 cm in diameter >1 cm 
GRADE V: Acute ischaemic change with 
oedema and haemorrhage : Acute ischaemia 
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(H) STATISTICAL ANALYSIS 
All the data was statistically analysed by Miss J. Hall of the 
Biostatistics Division of the South African Medical Research Council. 
Blood pressure, pulse, blood gases, haemoglobin, weight, neuro-
logical and pathological outcome were analysed and compared to 
determine whether high dose barbiturate management had any 




As detailed in the previous chapter, the brains of 30 monkeys were 
made transiently ischaemic by occluding the middle cerebral 
artery for 4 hours. Fifteen monkeys constituted a control group 
and the remaining 15 the test group. Pentobarbital, 30 mg/kg, 
was given intravenously after a delay of an hour. 
Various parameters were recorded and analysed as is shown on pages 
42 to 73 and summarized in Tables I and II . The statistical 
analyses were done to ascertain the comparability of the 2 groups 
and the possible effect in the neurological and pathological 
outcome of high dose barbiturate treatment. 
(A) CASE HISTORIES 
To introduce uniformity, zero (0) hour was taken to be the moment 
of vessel occlusion, usually about 1! hours from the time the monkey 
was intubated. The day of the experiment was called Day 1. 
41 
Blood pressure was recorded as the mean pressure in mmHg and pulse 
and respiration as the rate per minute. P02 and PC02 were expressed 
as mmHg and the pentobarbital levels in micrograms/ml (Ug/ml). 































































































































































































































































































































































































































































































































































































































































































































































































































































































































Weight 7 kg 
Anaesthesia: As described in the method. 
Surgery: As described in the method. Minimal 
blood loss with no subarachnoid 
haemorrhage. Occlusion performed 
without any problems. 
-1 0 ! 1 H 2 2! 3 3! 4 
80 80 80 70 70 80 80 90 100 90 
100 100 100 100 100 100 100 100 100 100 
14 14 14 14 14 14 12 12 12 12 
7,47 7,47 7,48 7,50 7,45 
144 131 · 161 155 162 
33 35 30 27 29 
105 105 
20,6 23,2 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequate at 7 hours, extubated and 
returned to cage . 








MONKEY 11 811 2: Weight 5 kg 













DAY 16 : 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. Occlusion 
performed without any problems. 
-1 0 ! 1 H 2 2! 3 3! 4 
120 100 100 90 90 120 120 100 105 90 
90 100 100 110 110 100 100 100 100 100 
16 16 16 16 16 16 16 16 16 16 
7,3 7,32 7,32 7,38 7,38 
107 114 100 100 150 
45 38 30 36 36 
75 75 
7,2 12, 1 
De-occlusion: Vessel patent . . 
Routine closure of all wounds. 
Breathing adequately at 5 hours, extubated and 
returned to cage . 
Alert, no deficit: GRADE I 
GRADE I 






















Weight 5,5 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. Occlusion 
performed without problems. 
-1 0 ! 1 H 2 2! 3 3! 
120 120 120 80 90 90 100 100 90 
60 60 60 60 60 60 60 60 60 
16 16 16 16 16 16 16 16 16 
7,53 7,6 7,6 7,5 
212 202 122 133 
28 35 37 35 
85 85 
20 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 8 hours, extubated and 
returned to cage . 




























Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
~ 1 H 2 2! 3 3~ 4 4~ 
100 110 120 90 85 100 110 115 100 100 100 
92 92 92 92 104 98 98 96 96 96 
15 15 15 15 15 15 15 15 15 15 
7,5 7,46 7,54 7,55 7,5 
138 131 163 155 171 
35 38 30 31 29 
100 100 
21 , 2 21 ,3 
De-occlusion: Segmental spasm of middle cerebral 
artery, cleared up over 10 minutes. 
Vessel patent. Routine closure of 
all wounds . 
Breathing adequately at 7 hours, extubated and 
returned to cage. 




















Weight 7 kg 
Anaesthesia: Routine. 
Surgery: 20 cc blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
-1 0 ! 1 H 2 2! 3 3! 4 
120 100 120 90 100 110 115 100 100 100 
86 96 96 96 96 96 96 96 96 96 
15 15 15 15 15 15 15 15 15 15 
7,56 7,54 7,6 
165 188 200 
18 20 22 
105 105 
19 21 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 6 hours, extubated and 
returned to cage. ' 























Weight 7 kg 
Anaesthesia: Routine. 
Surgery: 
-1 0 ! 
Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion perfonned without problems. 
1 H 2 2! 3 3! 4 
. 49 
4! 
110 120 120 90 80 110 115 120 120 120 120 
70 65 65 65 70 70 70 70 70 
15 15 15 15 15 15 15 15 15 
7,45 7,56 7,5 
219 191 131 
49 23 26 
105 105 
23 ,: 
De-occlusion: Vessel patent. 
Routine closure of wounds. 
Breathing adequately at 5 hours, extubated and 
returned to cage . 





















Weight 6 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
-1 .o ! 1 H 2 2! 3 3! 4 
130 120 110 85 70 95 90 90 90 100 
84 84 90 100 90 90 90 90 90 90 
12 12 16 16 16 16 16 16 16 16 
7,4 7,37 7,39 7,39 7,4 
153 196 148 106 200 
39 46 46 44 46 
90 90 
14 20 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 7 hours, extubated and 
returned to cag~. 
In coma: GRADE IV 
Dead: GRADE V 





















Weight 6 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion perfonned without problems. 
-1 0 l 1 H 2 2! 3 3i 4 2 
100 100 130 90 100 110 115 120 120 120 
70 70 70 80 100 100 100 100 100 100 
15 15 15 15 15 15 15 15 15 15 
7,51 7,51 7,52 7,5 7,5 
220 165 180 200 140 
18 20 26 26 26 
90 90 
19 25 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 7 hours. Extubated and 
returned to cage. 
































Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
i 1 H 2 2! 3 3i 4 
110 80 70 110 120 110 11'0 110 
100 100 130 130 130 120 120 120 
16 16 16 16 16 16 16 '16 
7,3 7,32 7,4 
100 100 110 
44 36 41 
60 60 
19 19 
De-occlusion: Vessel patent. 
Breathing: 
Routine closure of all wounds. 
Remained in deep coma, without any 
attempt at breathing . Had a 
cardiac arrest at 9 hours. 

























Weight 6,5 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
-1 0 i 1 H 2 2! 3 3! 4 
110 110 120 100 100 120 120 120 120 120 
76 76 76 88 84 86 84 86 86 86 







De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 6 hours, extubated and 
returned to cage. 

























Weight 7 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion perfonned without problems. 
-1 0 ! 1 H 2 2! 3 3! 
100 110 110 100 100 115 120 120 120 
90 90 96 96 110 110 110 110 110 







De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. 
St i 11 in coma . 























Weight 6,5 kg 
Anaesthesia: Routine. 
Surgery: 
-1 0 ! 
110 110 120 
90 90 110 




·Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
1 H 2 2! 3 3! 4 4i 
80 85 95 100 100 120 120 120 
110 110 110 110 110 110 110 110 





21 ,9 29,9 21 
De-occlusion : Vessel patent. 
Breathing: 
Routine closure of all wounds. 
Monkey remained in a deep coma. 
Made some respiratory effo rt at 5 hours 
but then gradually deteriorated and died 
of a cardiac arrest at 10 hours. 
Dead: GRADE V 
Brain removed. 
















Weight 4 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
-1 0 ! 1 H 2 2! 3 3! 4 
110 100 120 80 90 90 95 95 100 100 
88 88 88 96 120 120 120 120 130 130 
15 15 15 15 15 15 15 15 15 ·15 
7,3 7 ,4. 7,4 
117 135 130 




De-occlusion : Vessel patent . 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 
Drowsy, left hemiplegia : GRADE IV 
Dead: GRADE V 






















Weight 6 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion perfonned without problems. 
-1 0 ! 1 H 2 2! 3 3l 4 
100 100 95 80 75 75 80 85 80 85 
90 96 96 96 108 108 108 108 108 108 
14 14 14 14 14 14 14 14 14 14 
7 ,6 . 7,5 7,44 
180 160 150 




De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequate at 5 hours. Extubated and 
returned to cage. 
























Weight 6,75 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
-1 0 ! 1 H 2 2! 3 3! 4 
90 100 90 90 80 95 100 100 110 110 
84 96 96 130 130 130 130 120 120 120 







De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 6 hours. Extubated and 
returned to cage. 




















Weight 5 kg 
Anaesthesia: Routine . . 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems • 
-1 0 i 1 H 2 2; 3 3! 4 
100 120 120 115 120 110 90 90 100 tOO 
130 140 150 150 150 150 150 150 150 150 
14 14 15 13 16 16 16 15 17 17 
7,32 7,33 7,38 
224 168 174 
45 41 46 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
20 cc blood loss when catheter was 
removed. 
Breath)ng adequately at 5 hours. Extubated and 
returned to cage. 




















Weight 6 kg 
Anaesthesia: Routine~ 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
-1 0 ~ · 1 H 2 2~ 3 3~ 4 4~ 
90 80 100 100 90 100 90 90 ·go 90 
90 90 90 90 80 80 80 80 80 80 
16 16 16 14 14 14 14 14 14 14 
7,56 7,6 7,6 7,5 7,5 
181 198 181 176 169 
I 27 24 27 31 33 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 







MONKEY 11 C11 3: 
DAY 1: 
TIME 









Weight 6 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion perfonned without problems • 
.. 
-1 0 ! 1 H 2 2! 3 3! 4 
100 100 120 120 120 120 120 120 120 120 
100 100 90 100 100 100 100 100 90 100 




De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 




















Weight 6 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion perfonned without problems . 
. . 
-1 0 ! 1 H 2 2~ 3 3! 4 
90 100 100 100 100 90 90 100 100 90 
80 80 80 80 80 80 80 80 80 80 




De-occlusion: Vessel patent. 
Routine closure of all wounds . 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 





















Weight 5 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems • 
' 
-1 0 ! 1 H 2 2! 3 3! 4 
130 130 130 130 130 125 130 130 130 125 
100 80 80 80 80 80 80 80 80 80 
16 16 16 16 16 16 16 16 16 16 
7,56 7,5 7,49 
240 186 195 
37 35 36 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 

































Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
.. 
! 1 H 2 2! 3 3! 4 4! 
110 110 100 130 100 120 120 120 120 
60 80 80 80 80 80 80 80 76 




·oe-occlusion: Vessel patentA 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 















Weight 6 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion perfonned without problems • 
-1 0 ! 1 H 2 2! 3 3! 4 
100 90 90 90 80 80 90 80 90 90 
70 70 70 70 80 80 80 80 80 80 




De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 
Dead : GRADE V 



















Weight 6 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems • 
-1 0 ~ · 1 H 2 2! 3 . 3~ 4 
100 100 100 90 100 95 100 90 90 90 
84 84 90 84 84 84 84 84 84 86 
16 16 16 16 16 16 16 16 16 16 
7,48 7,38 7,47 7,45 
233 199 192 185 
40 31 28 28 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 
Drowsy, hemiplegic: GRADE IV 
Dead: GRAD E V 


















DAY 18 : 
Weight 7 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems . 
• 
-1 0 ! 1 n 2 2} 3 3! 4 
100 120 120 130 120 120 120 100 110 120 
88 88 88 84 70 70 76 72 80 84 




De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 




















Weight 4 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems • 
-1 0 ! 1 H 2 2! 3 3! 4 
11 o 90 115 100 90 90 90 90 90 110 
90 90 90 92 90 90 90 94 90 90 
12 12 12 16 16 16 16 16 16 16 
7,31 7,26 7,3 7,3 
125 176 224 183 
1 52 45 44 41 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 





















Weight 7 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
. 
2! I -1 0 ! 1 H 2 3 3! 4 
120 120 120 1151110 110 95 100 100 110 
I 
I 
80 80 ! 
I 
84 84 I 88 88 88 88 86 90 





De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 



















DAY 2: . 
DAY 9: 
Weight 6,5 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
0cc 1 us ion performed without prob 1 ems • 
. , 
I 
-1 o ! 1 H 2 2! 3 3! 4 
120 130 120 110 1130 120 120 120 120 115 
92 92 i I 98 98 1 98 98 98 98 100 100 
I 1 
14 14 14 14 
l 
14 14 14 14 14 14 
7,36 7,35 7,48 
160 171 201 
50 46 30 
19 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 





















D.l\ Y 14: 
Weight 5,5 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 




-1 0 l. 1 2 2! I 3 3! 4 2 
I 
130 130 11. 0 1101110 120 120 120 110 100 
80 84 1 96 96 96 96 I 90 90 90 90 
i 
I 
14 14 14 14 14 14 14 14 14 14 
17 ,36 7,35 7,36 
63 109 131 
50 44 41 
18 
De-occlusion: Vessel patent. 
Routine closure of all wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 






















Weight 4 kg 
Anaesthesia: Routine 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
' ; 
-1 0 ! 1 H 2 2! I 3 3! 4 
. 
100 90 100 90 90 90 85 80 90 90 
I 110 110 l 120 l 130 ! 130 1130 130 130 130 130 
: I 
I 






De-occlusion: Vessel patent. 
Routine closure of all wounds. · 
Breathing adequately at 5 hours. Extubated and 
returned to cage. 





















Weight 6 kg 
Anaesthesia: Routine. 
Surgery: Minimal blood loss. 
No subarachnoid haemorrhage. 
Occlusion performed without problems. 
- 1 0 ! 1 H 2 2! 3 3! 4 
I 
100 100 100 100 95 100 105 11 o 105 105 
841 
I 
84 84 84 84 I 84 84 84 84 84 
' 
I 
13 13 I 13 13 13 13 13 13 13 )3 




De-occlusion: Vessel patent. 
Routine closure of a 11 wounds. 
Breathing adequately at 5 hours. Extubated and 
returned to cage . 







(B) COMPARABILITY OF THE GROUPS 
WEIGHT 
The monkeys weighed between 4 and 7 kg, with an average of 
5,73 (!0,8) kg in the control and 5,86 (!0,99) kg in the barbiturate 
group. This difference was not statistically significant. The 
weight distribution is shown in Table III and again no difference 
was shown between the two groups. 
BLOOD PRESSURE AND PULSE (BP AND PULSE) 
Blood pressure and pulse varied considerably, depending on the depth 
of anaesthesia and the barbiturate dosage, as is shown in Tables I 
and I I. + In the control group the BP averaged 105,4 mmHg (-11,83) 
and the pulse rate was 91 ,13 (!19,19). The barbiturate group 1 s 
BP was recorded as two sets, before and after pentobarbital was 
given. BP averaged 108,8 (!11,40) and 97,6 (!10,23) mmHg 
respectively, with a pulse rate of 92,8 (!14,67). This slightly 
lower BP after pentobarbital treatment was statistically differ~nt 
but not for the other values recorded. 
Multiple blood gas determinations were made as is shown in 
Tables I and II. On the average, the barbitu rate group showed a 
+ slight respiratory alkalosis with the pH 7,47 (-0,09), p02 159,26 
mmHg (!32,20) and a pC02 of 32,53 (!8,08). The control group had 
(
+ + + a pH of 7,43 -0,08), p02 170,9 (-32,86) and pC02 35,8 (-6,5) mmHg. 
These differences though were not statistically significant. 
74 
HAEMOGLOBIN (Hb) 
This was detennined only in the last 10 monkeys as is shown in 
Tables I and II. + The control group averaged 17,2 (-t,48) and the 
barbiturate group 16,6 (!2,9) gm%, with no statistical difference. 
STATISTICAL COMPARABILITY 
No st atistical differences were shown in these parameters, making 
this two well matched groups. 
· 75 
76 
WEIGHT DISTRIBU TION 
TABLE III 
Weight - Kg 4-4,75 5-5,5 6-6,5 6,75-7 
Control 2 3 8 2 
Barbiturate 2 2 7 4 
Total 4 5 15 6 
(C) NEUROLOGICAL OUTCOME 
Neurological assessments for analyses and comparing were those for 
Day 2 and at sacrifice. 
The outcome on Day 2 for the 2 groups is shown in Table IV. It 
is clear from this table that 26,6% had no neurological deficit, 
26,6% died in the acute phase and 46,6% developed some neurological 
deficit. 
The outcome was virtual'ly identical in the 2 groups with no 
statistical difference shown. 
During the subsequent 2 weeks some of the animals improved whereas 
others died as is shown in Table V. 
ln the control group, 2 of the Grade III monkeys improved and 4 of 
the barbiturate monkeys, to Grade Il. However, 1 Grade IV monkey 
in the control group and 2 barbiturate monkeys deteriorated and 
died. The remainder of the monkeys did not change their neurolo-
gical status. The final outcome was also not statistically 
different between the 2 groups. 
(D) PATHOLOGICAL OUTCOME 
Details and photographs of the pathological classification adopted 
are shown on pages 79 to 81 and a graphic illustration of each 















(at DAY 2) 
TABLE IV 
I II II I IV 
4 2 4 1 
4 1 4 2 




I II I II IV 
4 4 2 0 
4 5 0 0 












CLASSIFICATION OF PATHOLOGICAL LESIONS 
4 
GRAVE I: NoJunai. bJuUn, fu;te.Jc.a.i Mpe.c.:t. 
NoJunai. H..i...6tology, Hand E S.:ta.,i.n. 
GRAVE II: Mi..CJt.oM.opic. in6Mc.tion. 
GRAVE III: Mac.JtoJ.ic.opic., well demMc.a;ted IJ.ic.ha.e.mic. in6Mc..t. 
< 1 c.m in diame.:tlte 
01tganizing in6a1tc..t. 
80 
GRAVE IV: Ma.CJz.oJ.ic.opic., we,U. demaJtc.a.,te.d Mc.ha.em,tc. in.6aJtc.t, in 
£.e.n.,ti_ooJzJn a.nd c.a.uda.,te. n.uc.le.M, > 1 cm in diamd.Vt. 
GRAVE V: Widu ph.e.a.d, a.c.u;te. M c.ha.emic. c.e,U. c.ha.ng e.J.i, w..Uh a edema a.nd 
pd.e.c.hia.l ha.emoMha.ge.. Al!.,60 aJte.M 06 6Mnk. in6aJtc.tion 
ph.e.J.ie.n;t, furu.bu;te.d in. the. aJte.a. 06 the. m,tddle. c.vr..e.bh.a.l 
a.h.tvr..y, 6~om the. ba.J.ia.l ga.ngl,ta. to the. c.o~e.x. 
St 
82 
PATHOLOGICAL LESIONS: ILLUSTRATED 
{ 
NORMAL ANATOMY: 
1 : Ca.u.date. nucle.u..6 
2: Thalamu..6 
3: Glo bu..6 pa.eLi.du..6 J 4: Pu;tame.n L e.n.-ti. 6 o Jun nucle.u..6 
6: I Mula. 
J: Tempottal lobe. 
8: I n.tVtn.al c.ap.6 ui.e. 
9: Colde.x 
MONKEY "B" 1: 
GRAVE IV: 
Puta.men and adjacent 
whi.;te matteA. 
MONKEY "B" 2: 
GRAVE III: 
Pu;tamen and ca.uda.,te nu.clew.,. 
83 
,. 
MONKEY "B" 3: 
GRAVE I: 
Nollma1. bl[.ain. 
MONKEY "B" 4: 
Nollma1. bJz. . cun. 
84 
MONKEY "B" 5: 
GRAVE V: 
Leo.i..on w.Uh a.c.u.te. .u.ic.ha.emlc. 
c.e.il. c.ha.ng e6 a.nd pde.c.lual 
ha.emo tvr.ha.g e.. 




MONKEY "B" 1: 
GRAVE V: 
Lv.,ian wi:th a.c.ute. .l6c.ha.e.mic. 
c.e.ll. c.ha.ngv.,, pete.c.fua.l 
ha.emoJrJtha.gv., a.nd a. .ta!tge. 
86 
1, 5 cm in6aJz.c..t in .the. pu.tame.n. 
MONKEY "B" 8: 
GRAVE V: 
Lv.,ia n. with a.c.ute. .l6 c.ha.e.mic. 
c.e.ll. c.ha.ng v., a.nd pete.c.fua.l 
ha.em a !Vl..ha.g e.. 
MONKEY "B" 9: 
GRAVE V: 
Luio n wUh a.c.u;te_ .ui c.haemic. 
c.e.U. c.hang u a.nd petec.hial 
haemoMhag e. 
MONKEY "B" 10: 
GRAVE II.: 
Mi.CJto;., c.o pie. .ui c.ha.emic. 
inoaJLction in the len.ti6oJun 
nu.c.le_w.,. 
87 
MONKEY "B" 11: 
GRAVE IV: 
In6a1tc.,t involving the i.nl.iui.alt 
c.oJt;te.x, la.tvr.al le.n.;ti.6oJun 
nu.c.le.U6 a.nd wWe. matteA. 
MONKEY "B" 12: 
GRAVE V: 
Ac.u;te. i-6 c.ha.e.mic. c.e.U c.ha.ngv.i. 
88 
MONKEY "B" 13: 
GRAVE V: 
Ac.u.te i6 c.ha.e.rru.c. c.e.U c.ha.ngeti 
w.Uh pe;tec.luai. ha.emaJVtha.ge. 
MONKEY "B" 14: 
GRAVE IV: 
Involving leritioaJun YW.c.leUJ.i 









' -· -:·~·:.::.) ........ '_i ! \ :,"'\ - ·· _:·· 
'· ... ,· j I \ .) 
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MONKEY "B" 15: 
GRAVE IV: 
Lehion. in .the. putame.n. 
MONKEY "C" 1: 
GRAVE V: 
Lehion W.Uh pe..te.c.Ma£ 
ha.emoJUr..ha.ge. a..nd a. ooc.al 
inocvz.c..t in .the. in6ula.. 
90 
MONKEY "C" 2: 
GRAVE I: 
No.tuna£ bll.cun. 
MONKEY "C" 3: 
GRAVE IV: 
Putame.n, 9.lobM pal.U.dM 
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MONKEY "C" 4: 
GRAVE IV: 
H ea.d o 6 .the c.auda..te. nu.d.e.M 
a.nd in.teJtna.l c.a.p.6 u.le. a.bcu:-
ting on .to .fentiooJUn nu.d.e.M. 
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MONKEY "C" 6: 
GRAVE II: 
Pa;tehy miCJ1.o.6eopie ~ehae.mle 
in6a.1tc;tion in the leriti6011.m 
nu.c1.e.U6. 
MONKEY "C" 7: 
GRAVE V: 
Lu,i,on .6howing a lMge 
in6a.1tc.,t ex.te.ncung 6~om the 
bMal ganglia to · the. eotrX.e.x. 
wilh pe.teehial haemoJVthage. 
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MONKEY "C" 8: 
GRAVE IV: 
Len.ti6o.tun nuc.leU6 and 
..i.nteJLnai.. c.ap,t, ul.e • 




MONKEY "C" 10: 
GRAVE I: 
NoJrmai. bltaJ..n. 
MONKEY "C" 11: 
GRAVE V: 
Ac..ute. ,i..,6 c..ha.em.ic.. c..ill c..han.g e...o 
wdh .tcvz.ge. 2 cm pa.1.e. in.6Mct 
.in .the. £.e.n;t:i601Un nu.de.U6. 
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MONKEY "C" 12: 
GRAVE IV: 
In6CV1..ct involving inJ.iu.lalt. 
c.o Id.ex, lenti 6 o 1m1 nu.c.leuJ.i 
and wru.-te mat:teA. 
MONKEY "C" 1 3: 
GRAVE IV: 
In6CV1..ct involving in~ul.a.!t 
cold.ex and adjacent wru.-te 
mat:teA. 
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MONKEY "C" 14: 
GRAVE III: 
Inoa.Jtc.:t involving ptLtamen 
a.nd intvr.na.t c.a.pf.i ule. 
MONKEY "C" 15: 
GRAVE V: 
Ac.!Lte if.i c.ha.e.mi..c. c.ell c.ha.ng u 
wil.h pexec.hia.l ha.emoJVtha.ge. 
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Table VI summarizes the distribution of lesions found in the 
pathological Grades II, III and IV. The 2 monkeys with Grade II 
lesions showed patchy changes in the lentiform nucleus, whereas 
the 11 monkeys with Grade III or IV lesions showed well developed 
ischaemic infarcts in the basal ganglia and insula. The Grade V 
lesions were widespread throughout the middle cerebral artery area 
involving basal ganglia, insula, white matter and cortex, with 
petechial haem0rrhage in all but 2. 
Table VII shows the pathological outcome with 33% in the control 
and 26% in the barbiturate group being normal or only showing micro-
scopic changes, whereas the remainder showed infarction and acute 
ischaemic changes. These findings were not statistically different 
in the 2 groups. 
(E) PATHOLOGICAL AND NEUROLOGICAL CORRELATIONS 
The pathological and neurological outcome for the combined group 
was compared for both the Day 2 and the neurological assessment 
at sacrifice. 
Table VIII shows the very good correlation found between the early 
neurological assessment on Day 2 and the eventual pathological 
lesion. Neurological Grades I and II monkeys showed Grades I 
and II pathological outcome, whereas the neurological Grades III, 
IV and V harboured Grades IV and V lesions. In 3 monkeys, however, 
there were discrepancies. Two neurologically intact monkeys 
(Grade I) harboured Grade III lesions in the putamen and in 1 
neurological Grade II monkey, no lesion could be found. These 
discrepancies, however~ were not statistically significant. 
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DISTRIBUTION OF GRADES II, III AND IV LESIONS 
TABLE VI 
Thalamus 1 
Lentiform nucleus 7 
Caudate 2 
Putamen 4 




GRADE I II III IV V TOTAL 
Control 4 1 1 5 4 15 Group 
Barbiturate 3 1 1 4 6 15 Group 
TOTAL 7 2 2 9 10 30 
PATHOLOGICAL AND NEUROLOGICAL CORRELATION 
(at DAY 2) 
TABLE VI II 
NEUROLOGICAL PATHOLOGICAL GRADE 
GRADE I II III IV 
I 6 2 
II 1 2 







Tables IX and X show the good pathological and neurological 
correlation for each group separately, whereas in Tables XI, XII 
and XIII, the neurological and pathological correlation on the day 
of sacrifice is shown. It is evident that 6 monkeys with Grade IV 
pathological lesions improved neurologically from Grade III to II. 
On the other hand, 1 monkey with a Grade IV lesion and 2 with 
Grade V lesions deteriorated from a neurological Grade IV and died. 
(F) WEIGHT CORRELATION WITH NEUROLOGICAL OUTCOME 
Table XIV shows the correlation of weight with neurological _outc6me 
in the 9 monkeys that were 5,5 kg or less and the 21 weighing more. 
It is evident that the lighter group did much better, 52% being 
Grades I or II, whereas in the heavier group only 28% were in these 
grades. 
The 2 monkeys with the neurological Grade I and Grade III 
pathological lesions, were both in the lighter group. This 
difference was statistically not significant. 
WEIGHT CORRELATION WITH PATHOLOGICAL OUTCOME 
Table XV shows the correlation with the pathological outcome. 
In the light group 33% of the monkeys were in t he Grade I or II 
groups whereas 28% of the heavier monkeys were i n t his group . 
This was not statistically significant . 
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(G) BARBITURATE BLOOD LEVEL (TABLE II) 
This was determined half an hour after the drug was given and 
again at de-occlusion of the vessel. Levels varied between 
16 ug/ml to 25 ug/ml, except in the monkey with an initial level 
of 29 ug/ml and in another monkey with levels of 8 ug/ml and 
12 ug/ml. There was no correlation between blood levels and 
out come. 
t02 
PATHOLOGICAL AND NEUROLOGICAL CORRELATION 
CONTROL GROUP - DAY 2 
TABLE IX 
NEUROLOGICAL PATHOLOGICAL GRADE 
GRADE I II III IV 
I 3 1 
II 1 1 
II I 4 
IV 1 
V 
PATHOLOGICAL AND NEUROLOGICAL CORRELATION 
BARBITURATE GROUP - DAY 2 
TABLE. X 
NEUROLOGICAL PATHOLOGICAL GRADE 
GRADE I II III IV 
I 3 1 
II 1 









PATHOLOGICAL AND NEUROLOGICAL CORRELATION 
(at Sacrifice) 
TABLE XI 
NEUROLOGICAL PATHOLOGICAL GRADE 
GRADE I II III IV 
I 6 2 







PATHOLOGICAL AND NEUROLOGICAL CORRELATION 
CONTROL GROUP - AT SACRIFICE 
TABLE XII 
NEUROLOGICAL PATHOLOGICAL GRADE 
GRADE I II II I IV 
I 3 1 
II 1 1 2 
I II 2 
IV 
V 1 
PATHOLOGICAL AND NEUROLOGICAL CORRELATION 
BARBITURATE GROUP - AT SACRIFICE 
TABLE XIII 
NEUROLOGICAL PATHOLOGICAL GRADE 
GRADE I II I II IV 
I 3 1 









WEIGHT COMPARED TO NEUROLOGICAL OUTCOME 
TABLE XIV 
NEUROLOGICAL I II III IV V GRADE 
4-5,5 kg 4 1 1 1 2 
6-7 kg 4 2 7 2 6 
WEIGHT COMPARED TO PATHOLOGICAL OUTCOME 
TABLE XV 
NEUROLOGICAL I II I II IV V GRADE 
4-5,5 kg 3 0 2 1 3 










This study investigated a suggested protective effect of barbitu-
rate treatment for transient focal cerebral ischaemia simulating 
the clinical event of a large cerebral vessel occlusion followed 
by revascularization. 
The experimental and control groups were well matched in all 
respects. No protective effect for high dose pentobarbital coma 
could be demonstrated and the neurological and pathological out-
comes were virtually identical in each group. Approximately a 
quarter of the animals were normal, a third developed neurological 
defects and a third died of their stroke. In each group a good 
correlation was found between the neurological and pathological 
outcome, which suggested that our simple, practical classification 
has merit. There were, however, 3 exceptions: 1 Grade II monkey 
showed no pathological abnormality and 2 Grade I monkeys showed 
Grade III pathological lesions in the putamen. This did not 
involve the internal capsule or cortex, perhaps explaining the 
absence of obvious neurological signs. 
Revascularization is reported to be beneficial in clinical and 
experimental strokes, Sundt et al (1974), Ojeman et al (1979), 
Kieck and Crowell (1979), Dujovny et al (1976), Morawetz et al 
(1978) and Jones et al (1981), where well selected cases with 
moderate neurological deficits may show dramatic improvement. 
The danger, however, of converting an ischaemic stroke into a 
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haemorrhagic one, as is well described in the clinical and experi-
mental literature, Wylie et al (1964), Crowell et al (1970), 
Morawetz et al (1978) and Hayashi et al {1978), was demonstrated in 
our animals. Those monkeys who suffered a major neurological 
deficit, developed haemorrhages of varying degrees in addition to 
· acute ischaemic cell changes and most of them went on to die without 
any improvement. 
The pathological lesions were present in the region supplied by the 
middle cerebral artery. The deep grey matter structures were 
involved in monkeys with less severe neurological deficits, whereas 
the insula and cortex were also infarcted in monkeys with more 
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severe neurological deficits. This is in keeping with the other v 
workers reporting on middle cerebral artery occlusion in the primate. 
It remains to examine why this experiment did not show a protective 
effect for barbiturates. The model and experiment will be examined 
in the light of what we know from the literature and any major 
discrepancies, if present, will be pointed out so as to explain 
this negative result as apparent or real. 
DELAYED TREATMENT 
Whereas in our model therapy was delayed for 1 hour, other workers 
delayed it for 15 minutes to 4 hou rs, Smith et al (1974), Mose·ley 
et al (1975 ) , Michenfelder et al (1976), Corkill et al (1976), 
Levy and Brierley (1979), Yonas et al (1980a,1981) and Selman et al 
(1981b), with some apparent therapeut i c effec t , although Corkill 
stated that no effect was shown if therapy was delayed for an hour 
or longer. 
DOSAGE REGIMES 
A considerable variety of dosage regimes have been reported to 
afford protection, from 60 mg/kg to as low as 15-20 mg/kg. 
Hankinson et al (1974) and Corkill et al (1978). The 30 mg/kg 
used in our study induced deep coma lasting 12 ho~rs or more, 
without causing major cardiovascular difficulties. 
BLOOD LEVELS 
Although the usefulness of barbiturate blood level detennination 
has been questioned by Miller (1979) and Bruce et al (1978), we, 
as others, Hoff et al (1975), Yonas et al (1979, 1981) and 
Weidler et al (1979), measured it as an indication of therapeutic 
efficacy. Whereas the levels in this study ranged between 
16-29 ug/ml without any correlation with the outcome, Yonas et al 
(1979), showed protection in 2 groups of dogs with levels between 
9-16 ug/ml and 19-49 ug/ml. In contrast, Weidler et al (1979), 
showed that all cats with levels over 30 ug/ml, died. 
DURATION OF THE OCCLUSION 
The earlier reports on barbiturate protection were for permanent 
focal ischaemia. Yonas et al (1981) and Selman et al (1981b), 
reported on apparent protection during 6 hours of transient occlu-




DISCUSSION OF THE LITERATURE ON TRANSIENT ISCHAEMIA 
The overall review of the literature made it clear that positive 
and negative results were shown for permanent focal ischaemia and 
global ischaemia with tremendous variability in models used and 
results reported. The reports by Yonas et al (1981) and Selman 
et al (1981b), showing apparent protection for 6 hours of transient 
occlusion, revealed some major discrepancies and raised a number of 
questions. 
Yonas et al (1981), showed no protection for pentobarbital treated 
animals, but only for thiopental. However, the statement that the 
11 grace 11 period to revascularization has been extended from 5 to 6 
hours is somewhat questionable, because this refers to a previous 
study by Dujovny et al (1976), in which occlusion of only 3, 4, 5 
and 7 hours is discussed in the text, though a 6 hour occlusion, 
showing infarction, is noted in a Table. Also, no control group 
without any barbiturate anaesthesia is available for comparison. 
It is also noteworthy that these workers showed similar extension 
of the "grace" period for dimethyl sulfoxide (DMSO) and prednisolone. 
Dujovny et al (1979). 
Similarly, Selman et al (1981b), reported protection in 6 hours of 
transient occlusion in a group of baboons treated and ventilated for 
96 hours. However, the control group breathed spontaneously, had a 
lower P02 and developed severely raised intracranial pressure, 
cerebral infarction and death . One can thus only speculate on how 
much the sedation and venti l ation played a role in the outcome. 
X 
Thus the model and variables in this experiment were not at variance 
with work which reported apparent protection under a variety of 





This study specifically investigated the theoretically attractive /-
situation of transient focal cerebral ischaemia simulating a 
cerebral vessel occlusion, treated with high dose pentobarbital and 
subsequent revascularization. No protection during the period of 
occl usion was shown for pentobarbital treated animals as compared 
to the untreated control animals. 
Revascularization after 4 hours resulted in a third of the animals 
remaining normal or suffering minor deficits, a third developi.ng 
significant deficits and the remaining third dying of their stroke. 
No statement can be made whether revascularization as such benefited 
these animals because they were sedated during the ischaemic period 
and no control group with permanent occlusion of the vessel was 
investigated. 
The experimental model used to simulate the clinical event worked 
satisfactorily and no major discrepancies compared to other reported 
works were apparent. 
Finally, the tremendous variation in reported results, ranging from 
apparent protection to no protection or to it even being detrimental, 
argues against a general protective effect in cerebral ischaemia. 
Certainly, the very conclusive outcome in this study specifi.cally 
showed no protection for delayed high dose barbiturate treatment in 





ANALYSIS OF BARBITURATE MANAGEMENT IN TRANSIENT FOCAL CEREBRAL 
ISCHAEMIA 
(A) VARIABLES 
In this study, 30 monkeys were randomly allocated to 2 groups; 
an experimental group and a control group. Initially the blood 
pressure in mm/Hg was measured in both groups. The barbiturate 
was administered to the experimental group and the blood pressure 
measured again in the experimental group. 




4. P02 mm/Hg 
5. PC02 mm/Hg 
6. Weight 
7. Haemoglobin 
The number of observations in the control and experimental groups 
are so small, that the assumptions on which the parametric tech-
niques of analysis are based, could not be checked. Also not being 
av-1are of previous work which would point to a preferred distribution 
type, it was decided to use non-parametric methods which make no 
assumptions about the underlying distributional structure of the 
<::I" ..... ..... 
VARIABLE 
Blood pressure (mm/Hg) 
before administration 
between groups 
Blood pressure (mm/Hg) 
after administration 
between groups 
Blood pressure in 
experimental group 

























CALCULATED VALUE TABULATED VALUE CONCLUSION 
X=0,05 X=0,10 
U = 89 64 72 Cannot reject the null hypothesis. 
U = 68,5 64 72 Cannot reject the null hypothesis 
at the 0,05 level but can reject 
it at X=0,10 level. 
T = 8 21 Reject the null hypothesis that 
the BP/mmHg does not differ before 
and after barbiturate is adminis-
tered in the experimental group. 
U = 80 64 72 Cannot reject the null hypothesis. 
U = 91 64 72 Cannot reject the null hypothesis. 
U = 81 64 72 Cannot reject the null hypothesis. 
U = 88 64 72 Cannot reject the null hypothesis. 
U = 82 64 72 Cannot reject the null hypothesis. 
U = 107 64 72 Cannot reject the null hypothesis. 
U = 84 64 72 Cannot reject the null hypothesis. 
U = 82 64 72 Cannot reject the null hypothesis. 
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population from which the sample is drawn, to analyse the data set. 
In comparing the measurements made on a variable in the control group 
with the corresponding variable in the experimental group, the Mann-
Whitney U test was used. It tests whether 2 samples represent 
populations which differ in central tendency (location). The 
general,null hypothesis: 
Ho: The variable under consideration from the 
monkeys in the control group and the expe-
rimental group is the same as tested against 
the alternative hypothesis. 
H1: The variable under consideration from the 
monkeys in the control group and the expe-
rimental group, differs. 
The hypotheses are two-tailed. A shift in the central tendency was 
being sought, without preference being given to any direction. 
In the case of the comparison of the blood pressure before and after 
the administration of the barbiturate, the Wilcoxon Matched Pairs 
Signed Rank Test was used, as the 2 sets of values are made on the 
same sample. The null hypothesis tested is: 
Ho: The blood pressure does not differ before 
and after the barbiturate is administered 
in the experimental group. 
Against the alternati ve hypothesis: 
H1: The blood pressure does differ after the 
administration of the barbiturate in the 
experimental group. 
This, again, is a two-tailed hypothesis test. 
The results of these tests are summarised in Table 1. 
From the conclusion column it can be deduced that at the 5% signi-
ficance level there is no significant difference between the expe-
rimental and control groups for the variables measured. The blood 
pressure variable between the groups after the administration of the 
barbiturates does show a difference at the 1% significance level. 
However, the blood pressure measurements within the experimental 
group, after the administration of the barbiturate, differs signi-
ficantly at the 5% level from the values taken before the adminis-
tration of the barbiturate. 
(B) NEUROLOGICAL AND PATHOLOGICAL OUTCOME 
To determine whether, in comparing the experimental and control 
groups, the barbiturate made a difference between the Pathological 
and Neurological outcomes - a Chi-square test was done for various 
groupings. 
The null hypothesis tested in each case was that: 
Ho: The grade is independent of barbiturates 
in the animals. 
The alternative hypothesis against which the null hypothesis is 
tested is: 
H1: The grade is dependent upon the presence 
of barbiturates in the animal. 
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Pathological Results: 
x2 = o,66 
The tabulated values are x!(o,o5) = 9,49 and x!(o,,o) = 7,78 
Conclusion: 
The pathological grade is independent of the level of 
barbiturates in the animal at both 5% and 1% significance 
levels. 
Neurological Results: 
For Day 2: 
x2 = o,67 
For results at sacrifice: 
x2 = 2,52 
The tabulated value at p = 0,05 significance level is 9,49 and 
at p = 0,10 significance level is 7,78 
Conclusion: 
Since x2 <x2(o,,o)< x2(o,o5) we cannot reJ·ect the null 
4 4 
hypothesis for both cases. The neurological grade is 
independent of the barbiturates administered to the 
monkeys can be concluded. 
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(C) NEUROLOGICAL AND PATHOLOGICAL CORRELATIONS 
In considering the relationships between the Pathological and 
Neurological grades from both the experimental and control groups 
combined, a Chi-square test was calculated. In both the patholo-
gical and neurological variables, grades had to be combined to get 
cells with enough observations, as the test is sensitive to the 
distribution of the frequencies. 
The hypothesis: 
Ho: The pathological and neurological grades 
are independent of one another was tested 
against 
H1 : The pathological and neurological grades 
are dependent on one another. 
x2 = 30,03 
x2(0,os) 
1 = 3,84 and 
x2(0,01) 
1 = 6,63 
Since the calculated x2 value is larger than the tabulated value, 
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the null hypothesis cannot be accepted and a very strong dependence 
is shown. A numerical value to thi s dependence can be assigned by 
ca l culating the Spearman Ra nk Co rre lation Coefficient. A correction 
factor to adjust for the large number of ties in the data had to be 
used in the calculation. The effect of the ties is to inflate the 
value of the correla ti on between Pathological and Neurological 
grades. 
The results are: 
For both groups combined, with the neurological grades measured 
on Day 2: 
r = 0,95 s 
For the experimental groups, with the neurological grades at Day 2: 
rs= 0,96 
Neurological grade at sacrifice 
rs= 0,91 
For the control group: 
Neurological grades at Day 2: r = 0,96 s 
Neurological grades at sacrifice: rs= 0,76 
There is a very strong positive dependence between the Neurological 
and Pathological grades for all groupings, except the control group 
with the neurological grade measured at the sacrifice. 
The significance of the Spearman's Rank Correlation was calculated 
For pathological and neurological observations for experimental and 
control groups combined, the t-value of significance for the 
Spearman's Rank Correlation Coefficient is: 
t = 15,90 
Tabulated value at 5% significance level is: 
t~8° 5 = 1,701' t~8° 01 = 3,64 
Since t < t 0•05 the correlation coefficient is significant . 28 
The correlation coefficient is significant for p << 0,0001 
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For experimental group: 
Neurological grades at Day 2: 
t = 12,24 t 0, 05 = 2,160 13 
Neurological grades at sacrifice: 
t = 3,52 
t0,001 = 
9 
t 0,05 = 2,262 
9 
4,781 
t 0,001 = 4,221 13 
Both correlation coefficients are significant for p 0,001 
For control group: 
Neurological grades at Day 2: 
t = 12i24 t 0,05 = 2,160 9 
t~, 001 = 4,781 
t 0,001 = 4,221 13 
Both correlation coefficients are significant for p 0,05. The 
correlation coefficient for the neurological grades at Day 2 is 
highly significant for p <<0,001. However, the significance for 
1.20 
the correlation coefficient for the neurological grades at sacrifice 
lies between 0,05 < p < 0,001. 
(D) WEIGHT DISTRIBUTION 
There is independence between t he weight of the control and 
barbiturate group of monkeys . 
Chi-square value 0,16 at p = 0,05; x2 = 3,84 
(E) WEIGHT VS NEUROLOGICAL OUTCOME 
Calculated x2 value 
x2 = 0,28 + o,s1 + o,38 + 0,22 
. -
= 1,99 
Tabulated x2 value (1° of freedom) at 5% significance level 
= 3,84 
x2 < x2, . •. cannot reject the null hypothesis. 
(F) WEIGHT VS PATHOLOGICAL OUTCOME 
Calculated x2 value 
x2 = o,o3 + 0,01 + 0,01 + 0,01 
. . 
= 0,66 
x2(0,os) = 3,84 
x2 << x2(0,0S) . ·. cannot reject null hypothesis of 
independence between pathological 
grades and weight. 
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